Insights

How to read the exclusivity stack, predict loss-of-exclusivity dates, and turn patent data into budget certainty Why Patent Blindness Is […]

The generic pharmaceutical industry runs on a contradiction. It is one of the most consequential public health interventions of the

Section 1: Why Your Patent Portfolio IS Your Balance Sheet A widespread assumption among early-stage biotech founders is that patents

Section 1: The Patent Bargain and the 20-Year Illusion The Foundational Quid Pro Quo The pharmaceutical patent system rests on

Key Takeaways (Article-Level) Section 1: What Makes a Generic Drug ‘Complex’ — And Why the Definition Carries a $50M Price

1. The Market Breakdown: Why the Classic Generic Model Is Financially Insolvent The Core Paradox of the Generic Industry The

Executive Overview Drug patent litigation in the United States is a designed feature of the pharmaceutical market, not a dysfunction.

The global pharmaceutical sector is defined by a widening rift between the industrial models of India and China. India holds

The biopharmaceutical sector is shifting its capital allocation toward living medicines. Biologics now represent nearly 50% of the industry’s total